Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

Marked Improvement in Four Regions of Body Consistent with Overall PASI

Response in REMICADE-Treated Patients

SAN ANTONIO, Feb. 4 /PRNewswire/ -- Data from an integrated analysis of three randomized, placebo-controlled trials showed patients with moderate to severe plaque psoriasis receiving REMICADE(R) (infliximab) achieved a consistently high level of skin clearance in each of the four body regions (head, trunk, lower and upper extremities) as measured by the Psoriasis Area Severity Index (PASI). At week 10 of the analysis, which included nearly 1,500 subjects, 71 percent of patients receiving REMICADE 3 mg/kg and 79 percent of patients receiving REMICADE 5 mg/kg achieved a PASI 75, or at least a 75 percent improvement in the chronic inflammatory condition, compared with three percent of patients receiving placebo (both P < 0.001). Additionally, 39 percent and 52 percent of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, achieved a PASI 90, or nearly complete skin clearance, versus one percent of patients receiving placebo (both P < 0.001). Investigators reported these findings at the 66th Annual Meeting of the American Academy of Dermatology.

In September 2006, the U.S. Food and Drug Administration (FDA) approved REMICADE (5 mg/kg) for the treatment of chronic severe plaque psoriasis. Following an initial three infusion treatments (induction regimen), REMICADE is given once every eight weeks, or as few as six times a year.

"This analysis shows that treatment with REMICADE resulted in a consistently high level of clinical response in each quadrant of the body evaluated by PASI, and the results were consistent with patients' overall psoriasis improvement," said Alan Menter, MD, dermatologist, Baylor Research Institute, Dallas, and lead study investigator. "REMICADE remains an important advancement and biologic treatment option for a broad spectrum of patients with severe psoriasis."

According to f
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 MC Medical, a subsidiary ... a Columbus, OH medical device company, ... FloShield laparoscopic and robotic visualization system in Japan ... for sale in Japan in the ... experience and an extensive product portfolio in endoscopic surgery market ...
(Date:8/22/2014)... Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - Free ... PNRA - Free Report ) as the Bear of the ... (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: SNY ... Report ). Here is a synopsis of all five ... The biotech bull market is far from over due ...
(Date:8/22/2014)... LA JOLLA , Cali ., Aug. ... Annual International Papillomavirus Conference shows that a therapy being developed ... including the two that cause 70 percent of all cervical ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker , Ph.D., who presented the findings at ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... CARMEL, Ind., Aug. 23, 2011 After several years ... device firms, Avant Healthcare Marketing has opened offices on ... expansion for the Midwest medical communications agency. ... Rod Julian, Strategic Brand Network Director for Avant. "But ...
... England, August 23, 2011 KalVista Pharmaceuticals ("KalVista"), ... edema (DME), has raised £8 million in a series A ... Life Sciences. The Company is developing novel, small ... the treatment of DME, a leading cause of adult visual ...
Cached Medicine Technology:Avant Healthcare Marketing Announces West Coast Expansion 2KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 2KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 3KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 4
(Date:8/23/2014)... York (PRWEB) August 23, 2014 ... filed on behalf of individuals who were ... hip replacement line continue to move forward in ... Bernstein Liebhard LLP reports. According to an Order ... bellwether trial program that would allow the litigation’s ...
(Date:8/23/2014)... 23, 2014 On Monday, August 18th, ... data breach suffered by Community Health Systems, which ... of 4.5 million records containing Personally Identifiable Information (PII) ... to Mandiant, who was engaged to investigate the incident, ... advanced group of cyber attackers based in China, who ...
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut Pro ... Vol.3, a customizable title tool for FCPX , ... dragging ProIntro Vol.3 in their timeline" says Christina Austin, CEO ... saver and i think our users will agree" , ProIntro ... made with Final Cut Pro X users in mind. Achieve ...
(Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2
... ... Onset Technology® today announce a partnership agreement to provide an advanced paging solution for ... enables Citipage customers to receive pages on their Blackberry smartphone via their current pager ... ...
... known that certain types of bacteria boost the immune ... how bacteria perform this essential task. Senior author ... in a featured article in the June 15, 2010, ... available online. Knight is professor and chair of the ...
... disorder in men , MONDAY, June 14 (HealthDay News) ... insecticides may increase a man,s risk of Parkinson,s disease, ... disease patients and a control group of 482 healthy ... for mutations in a gene called ABCB1 and assessed ...
... some drugs, smoking increased vision problems, studies found , ... helps guard against cataracts, while certain medications raise the ... new studies suggest. , And a third study finds ... another disease that robs people of their sight. , ...
... around 200,000 people in Sweden have been diagnosed with ... be helped by mechanical heart pumps, reveals a thesis ... a total of 99 patients with life-threatening heart failure ... long-term circulatory support., "Two-thirds of these patients survived," says ...
... nurse in The University of Texas MD Anderson Cancer ... the 2010 Ethel Fleming Arceneaux Outstanding Nurse-Oncologist Award, made ... of MD Anderson,s clinical faculty, patient care administration and ... selecting Fields for the annual award, the institution,s highest ...
Cached Medicine News:Health News:Onset Technology and Citipage Ltd. Partner to Deliver Advanced Paging Messages to Smartphones 2Health News:Onset Technology and Citipage Ltd. Partner to Deliver Advanced Paging Messages to Smartphones 3Health News:How bacteria boost the immune system 2Health News:Diet, Meds and Smoking Linked to Eye Disease Risks 2Health News:Diet, Meds and Smoking Linked to Eye Disease Risks 3Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 2Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: